M R Sertoli - JoVE Visualize

Showing results (61-70 of 79) with videos related to

Pageof 8

Sort By:

British Journal of Cancer|February 1, 1994

Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancerA Ardizzoni, M Venturini, M R Sertoli, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemiaL Del Mastro, M Venturini, R Lionetto, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanomaE Bajetta, A Di Leo, M G Zampino, et al.

Annals of Surgical Oncology|May 26, 1999

Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori GroupP Queirolo, M Ponte, M Gipponi, et al.

International Journal of Cancer|February 15, 1989

Phenotypic and functional characteristics of tumor-associated lymphocytes in patients with malignant ascites receiving intraperitoneal infusions of recombinant interleukin-2 (rIL-2)G Melioli, E Baldini, M C Mingari, et al.

Anticancer Research|March 4, 2000

Adoptive immunotherapy of advanced solid tumors: an eight year clinical experienceC Semino, L Martini, P Queirolo, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1996

Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancerM Venturini, L Del Mastro, F Testore, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2006

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanomaE Bajetta, M Del Vecchio, P Nova, et al.

Breast (Edinburgh, Scotland)|April 1, 2017

Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysisF Poggio, M Ceppi, M Lambertini, et al.

Melanoma Research|December 22, 1999

Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)M R Sertoli, P Queirolo, E Bajetta, et al.

Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:

Pageof 8

British Journal of Cancer|February 1, 1994

Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancerA Ardizzoni, M Venturini, M R Sertoli, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1997

Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemiaL Del Mastro, M Venturini, R Lionetto, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanomaE Bajetta, A Di Leo, M G Zampino, et al.

Annals of Surgical Oncology|May 26, 1999

Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori GroupP Queirolo, M Ponte, M Gipponi, et al.

International Journal of Cancer|February 15, 1989

Phenotypic and functional characteristics of tumor-associated lymphocytes in patients with malignant ascites receiving intraperitoneal infusions of recombinant interleukin-2 (rIL-2)G Melioli, E Baldini, M C Mingari, et al.

Anticancer Research|March 4, 2000

Adoptive immunotherapy of advanced solid tumors: an eight year clinical experienceC Semino, L Martini, P Queirolo, et al.

Cancer Chemotherapy and Pharmacology|January 1, 1996

Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancerM Venturini, L Del Mastro, F Testore, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2006

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanomaE Bajetta, M Del Vecchio, P Nova, et al.

Breast (Edinburgh, Scotland)|April 1, 2017

Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysisF Poggio, M Ceppi, M Lambertini, et al.

Melanoma Research|December 22, 1999

Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)M R Sertoli, P Queirolo, E Bajetta, et al.

Pageof 8